JP2013545779A5 - - Google Patents

Download PDF

Info

Publication number
JP2013545779A5
JP2013545779A5 JP2013543710A JP2013543710A JP2013545779A5 JP 2013545779 A5 JP2013545779 A5 JP 2013545779A5 JP 2013543710 A JP2013543710 A JP 2013543710A JP 2013543710 A JP2013543710 A JP 2013543710A JP 2013545779 A5 JP2013545779 A5 JP 2013545779A5
Authority
JP
Japan
Prior art keywords
amino
imidazo
cyclopropyl
pyrazin
benzamide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013543710A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013545779A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2011/072591 external-priority patent/WO2012080236A1/en
Publication of JP2013545779A publication Critical patent/JP2013545779A/ja
Publication of JP2013545779A5 publication Critical patent/JP2013545779A5/ja
Pending legal-status Critical Current

Links

JP2013543710A 2010-12-17 2011-12-13 過剰増殖性障害の治療におけるmps−1およびtkk阻害剤として使用するための6置換イミダゾピラジン Pending JP2013545779A (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP10195635 2010-12-17
EP10195635.7 2010-12-17
EP10195699.3 2010-12-17
EP10195699 2010-12-17
EP11170158.7 2011-06-16
EP11170163 2011-06-16
EP11170158 2011-06-16
EP11170163.7 2011-06-16
PCT/EP2011/072591 WO2012080236A1 (en) 2010-12-17 2011-12-13 6-substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders

Publications (2)

Publication Number Publication Date
JP2013545779A JP2013545779A (ja) 2013-12-26
JP2013545779A5 true JP2013545779A5 (enExample) 2015-02-05

Family

ID=45218758

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013543710A Pending JP2013545779A (ja) 2010-12-17 2011-12-13 過剰増殖性障害の治療におけるmps−1およびtkk阻害剤として使用するための6置換イミダゾピラジン

Country Status (6)

Country Link
US (1) US20140135319A1 (enExample)
EP (1) EP2651945A1 (enExample)
JP (1) JP2013545779A (enExample)
CN (1) CN103429592A (enExample)
CA (1) CA2821819A1 (enExample)
WO (1) WO2012080236A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60100852A (ja) * 1984-09-28 1985-06-04 Hitachi Ltd 情報伝送方法
TWI541243B (zh) 2010-09-10 2016-07-11 拜耳知識產權公司 經取代咪唑并嗒
GB201212513D0 (en) * 2012-07-13 2012-08-29 Ucb Pharma Sa Therapeutic agents
WO2014020041A1 (en) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
WO2014020043A1 (en) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinations for the treatment of cancer
NZ707432A (en) 2012-11-16 2020-01-31 Univ Health Network Pyrazolopyrimidine compounds
EA031601B1 (ru) * 2013-07-31 2019-01-31 Джилид Сайэнс, Инк. Ингибиторы syk
JP6095857B2 (ja) * 2013-11-15 2017-03-15 ユニバーシティ・ヘルス・ネットワーク ピラゾロピリミジン化合物
DK3105218T3 (da) 2014-02-13 2019-11-04 Incyte Corp Cyclopropylaminer som lsd1-inhibitorer
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
TW201613860A (en) 2014-02-13 2016-04-16 Incyte Corp Cyclopropylamines as LSD1 inhibitors
TWI720451B (zh) 2014-02-13 2021-03-01 美商英塞特控股公司 作為lsd1抑制劑之環丙胺
WO2016007727A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
US9695168B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,5-α]pyridines and imidazo[1,5-α]pyrazines as LSD1 inhibitors
WO2016007736A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyrazines as lsd1 inhibitors
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
PE20180455A1 (es) 2015-04-03 2018-03-05 Incyte Corp Compuestos heterociclicos como inhibidores de lsd1
CN114592061A (zh) 2015-04-17 2022-06-07 荷兰转化研究中心有限责任公司 用于ttk抑制剂化疗的预后生物标记
UA126277C2 (uk) 2015-08-12 2022-09-14 Інсайт Корпорейшн Солі інгібітору lsd1
MA44725A (fr) 2016-04-22 2019-02-27 Incyte Corp Formulations d'un inhibiteur de lsd1
BR112019021282A2 (pt) * 2017-04-12 2020-05-19 Magenta Therapeutics Inc antagonistas de receptor aril hidrocarboneto e usos dos mesmos
WO2019089826A1 (en) * 2017-10-31 2019-05-09 Magenta Therapeutics Inc. Compositions and methods for the expansion of hematopoietic stem and progenitor cells
LT3792260T (lt) * 2018-05-08 2024-10-25 Nippon Shinyaku Co., Ltd. Azabenzimidazolo junginiai ir farmacinis preparatas
WO2020047198A1 (en) 2018-08-31 2020-03-05 Incyte Corporation Salts of an lsd1 inhibitor and processes for preparing the same
CA3115825A1 (en) * 2018-10-17 2020-04-23 Magenta Therapeutics, Inc. Methods of treating cancer with aryl hydrocarbon receptor antagonists

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5011472A (en) 1988-09-06 1991-04-30 Brown University Research Foundation Implantable delivery system for biological factors
AU2003275031B2 (en) * 2002-09-23 2006-08-17 Schering Corporation Novel imidazopyrazines as cyclin dependent kinase inhibitors
AU2003272476B2 (en) * 2002-09-23 2007-07-05 Schering Corporation Imidazopyrazines as cyclin dependent kinase inhibitors
US7576085B2 (en) * 2002-09-23 2009-08-18 Schering Corporation Imidazopyrazines as cyclin dependent kinase inhibitors
US7157460B2 (en) * 2003-02-20 2007-01-02 Sugen Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
US7186832B2 (en) * 2003-02-20 2007-03-06 Sugen Inc. Use of 8-amino-aryl-substituted imidazopyrazines as kinase inhibitors
WO2007032936A2 (en) * 2005-09-09 2007-03-22 Schering Corporation Azafused cyclin dependent kinase inhibitors
TW200803863A (en) * 2005-11-10 2008-01-16 Schering Corp Method for inhibiting protein kinases
PE20070805A1 (es) * 2005-11-10 2007-08-13 Schering Corp Imidazopirazinas como inhibidores de proteinquinasa
CN101516883A (zh) 2006-06-06 2009-08-26 先灵公司 作为蛋白激酶抑制剂的咪唑并吡嗪化合物
EP2364702A3 (en) * 2006-09-05 2012-01-25 Emory University Kinase inhibitors for preventing or treating pathogen infection and method of use thereof
CN101589045A (zh) * 2006-11-08 2009-11-25 先灵公司 作为蛋白质激酶抑制剂的咪唑并吡嗪
GB0716292D0 (en) 2007-08-21 2007-09-26 Biofocus Dpi Ltd Imidazopyrazine compounds
US20110118238A1 (en) * 2007-08-23 2011-05-19 Astrazeneca Ab 2-anilinopurin-8-ones as inhibitors of ttk/mps1 for the treatment of proliferative disorders
EP2424537B1 (en) * 2009-04-29 2015-07-08 Bayer Intellectual Property GmbH Substituted imidazoquinoxalines
TW201107329A (en) 2009-07-30 2011-03-01 Oncotherapy Science Inc Fused imidazole derivative having ttk inhibitory action
JP5728683B2 (ja) 2009-09-04 2015-06-03 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH チロシンスレオニンキナーゼ阻害剤としての置換アミノキノキサリン
EP2343295A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridine derivates
EP2343294A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Substituted triazolopyridines
EP2343297A1 (en) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
US9468642B2 (en) * 2010-03-18 2016-10-18 Bayer Intellectual Property Gmbh Imidazopyrazines
US9199999B2 (en) * 2010-06-01 2015-12-01 Bayer Intellectual Property Gmbh Substituted imidazopyrazines
WO2012080234A1 (en) * 2010-12-17 2012-06-21 Bayer Pharma Aktiengesellschaft Substituted 6-imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders
JP5964853B2 (ja) * 2010-12-17 2016-08-03 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH 過増殖性障害の処置におけるmps−1およびtkk阻害剤としての使用のための、6−チオ置換イミダゾピラジン類
WO2012080230A1 (en) * 2010-12-17 2012-06-21 Bayer Pharma Aktiengesellschaft 6 substituted imidazopyrazines for use as mps-1 and tkk inhibitors in the treatment of hyperproliferative disorders

Similar Documents

Publication Publication Date Title
JP2013545779A5 (enExample)
JP2013515729A5 (enExample)
HRP20201337T1 (hr) Inhibitori lizin-specifične demetilaze-1
JP2013537174A5 (enExample)
JP2016523911A5 (enExample)
RU2507204C2 (ru) Положительные аллостерические модуляторы м1-рецепторов на основе пираниларилметилбензохиназолинона
CN111601593B (zh) P38激酶抑制剂降低dux4和下游基因表达以用于治疗fshd
HRP20251479T1 (hr) Pesticidno aktivni kondenzirani biciklički heteroaromatski spojevi
HRP20240994T1 (hr) Spoj inhibitora jak i njegova uporaba
SI3083586T1 (en) The new carboxamides, the process of their manufacture, the pharmaceutical preparations they contain and their use for the manufacture of medicinal products
SI3183247T1 (en) Aminopyrimidinyl compounds as inhibitors of JAK
JP2006520805A5 (enExample)
JP2019504821A5 (enExample)
RU2016124176A (ru) Композиции тетрагидрохинолинов в качестве ингибиторов бромодомена вет
JP2011520908A5 (enExample)
HRP20160360T1 (hr) Supstituirani imidazopiridazini
JP2016528298A5 (enExample)
JP2012532931A5 (enExample)
JP2014521711A5 (enExample)
JP2013523884A5 (enExample)
RU2015152576A (ru) Производные индолин-2-она или пирролопиридин/пиримидин-2-она
JP2012501312A5 (enExample)
JP2011506417A5 (enExample)
JP2014522855A5 (enExample)
JP2014501269A5 (enExample)